Evidence map›Paper›PMID 40563647›Full record

ReviewCancers2025

An Assessment of Surgical Outcomes in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review and Meta-Analysis of Surgical Interventions.

Abdel-Hameed Al-Mistarehi, Khaled J Zaitoun, Jawad Khalifeh, Max A Saint-Germain, Melanie Alfonzo Horowitz, Abdul Karim Ghaith, Chase H Foster, Shoshana Braverman, Avi N Albert, Usama AlDallal and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abdel-Hameed Al-MistarehiDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-4713-8536
Khaled J ZaitounFaculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
Jawad KhalifehDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Max A Saint-GermainDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Melanie Alfonzo HorowitzDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Abdul Karim GhaithDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-9600-609X
Chase H FosterDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2637-2331
Shoshana BravermanStern College for Women, Yeshiva University, New York, NY 10033, USA.
Avi N AlbertSchool of Medicine, Meharry Medical College, Nashville, TN 37208, USA.
Usama AlDallalSchool of Medicine, Medical University of Bahrain, Adliya P.O. Box 15503, Bahrain.
Allan BelzbergDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-1158-2117
Sang LeeDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
Nicholas TheodoreDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-5355-2683
Ilya LauferDepartment of Neurosurgery, New York University Langone Health, New York, NY 10016, USA.
Daniel LubelskiDepartment of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-9403-9509

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesMalignant peripheral nerve sheath tumors (MPNSTs) are aggressive malignancies with a challenging prognosis, especially for patients with Neurofibromatosis type 1 (NF1). Their low incidence necessitates comprehensive studies to investigate the survival outcome.

methodsWe conducted a systematic review and meta-analysis, including data from 16 studies and 4265 patients, to explore surgical outcomes and survival rates, focusing on time-related outcomes, including overall survival (OS), progression-free survival (PFS), and recurrence rate.

resultsThe analysis revealed that the OS rate was 86% [95% CI: 75-97%] at 1 year, decreasing to 60% [95% CI: 45-75%] at 3 years, and further declining to 47% [95% CI: 35-58%] by 5 years. For PFS, the 1-year rate was 61% [95% CI: 25-98%], which remained similar at 62% [95% CI: 35-89%] for 3 and 5 years. In NF1-associated MPNSTs, the 1-year OS was relatively high at 93% [95% CI: 83-100%], but it dropped to 68% [95% CI: 53-84%] at 3 years and further to 50% [95% CI: 31-68%] at 5 years. Additionally, the hazard ratio indicated a 38% lower survival rate in NF1 patients than those with sporadic MPNSTs when data were presented in the same study. Recurrence rates were high, with 56% of patients experiencing a relapse, primarily as local recurrences (70.6%). Mortality was significant, with over 50% of patients dying within an average follow-up period of 33.45 months.

conclusionsMPNSTs, particularly in NF1 patients, are associated with poor prognosis and high recurrence rates. These results underline the necessity of targeted therapeutic strategies and improved programs for screening, mainly through a multidisciplinary approach to optimize management.

Indexed as

malignant peripheral nerve sheath tumorsmortalityMPNSTPFSprogression-free survivalrecurrencesurvival

Identifiers

PMID40563647
PMCPMC12190973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.